Overview

Cladribine and Rituximab as Remission Induction Therapy Followed By Rituximab and Stem Cell Mobilization in Treating Patients With CLL

Status:
Completed

Trial end date:
2010-10-01

Target enrollment:

Participant gender:

Summary

RATIONALE: Drugs used in chemotherapy, such as cladribine, use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Combining cladribine with rituximab may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving cladribine and rituximab as remission induction therapy together with rituximab and stem cell mobilization in treating patients with chronic lymphocytic leukemia.

Phase:

Phase 2

Details

Lead Sponsor:

Swiss Group for Clinical Cancer Research

Treatments:

Cladribine
Cyclophosphamide
Doxorubicin
Lenograstim
Liposomal doxorubicin
Prednisone
Rituximab
Vincristine